Skip to content

Another Disappointing Vitamin D3 and Cancer Result

Another disappointing result for vitamin D3, this time looking at metastatic colorectal cancer progression and survival. For years, there was hope that taking high doses of vitamin D3 would help in preventing all sorts of cancers or would help in the treatment of cancer.  But the studies keep finding no effects from vitamin D3 supplements.

Researchers found that adding high dose vitamin D3 to standard chemotherapy plus bevacizumab did not improve progression-free survival (PFS) in patients with previously untreated metastatic colorectal cancer, when compared to those who received the same treatment except that they received a daily standard dose vitamin D3 supplement.

High dose vitamin D3 was 8000 IU daily for 14 days, followed by 4000 IU daily. Standard dose vitamin D3 (the  control group) was 400 IU daily.

Excerpts from Medscape: Does High-Dose Vitamin D3 Supplementation Improve CRC Survival?

High-dose vitamin D3 supplementation added to standard chemotherapy plus bevacizumab does not improve progression-free survival (PFS) compared with standard-dose vitamin D3 in patients with previously untreated metastatic colorectal cancer (mCRC). Among 455 randomized patients, median PFS was 11.8 months in the high-dose group vs 10.3 months in the standard-dose group, with no significant differences in objective response rates or overall survival.

METHODOLOGY

  • The SUNSHINE phase 2 randomized clinical trial demonstrated that high-dose vitamin D3 added to standard treatment improved PFS [progression-free survival] compared with standard-dose vitamin D3 in patients with previously untreated mCRC [metastatic colorectal cancer]. The SOLARIS trial was conducted to confirm the findings from the SUNSHINE trial.
  • Researchers conducted the double-blind phase 3 randomized SOLARIS trial in 455 patients with previously untreated mCRC through the National Clinical Trials Network in the United States from October 2019 to December 2022, with database freeze on July 15, 2024.
  • Patients received investigator’s choice chemotherapy consisting of modified FOLFOX6 (5-fluorouracil, leucovorin, oxaliplatin) or FOLFIRI (5-fluorouracil, leucovorin, irinotecan) plus bevacizumab 5 mg/kg intravenously every 2 weeks, randomly assigned 1:1 to receive either high-dose vitamin D3 (8000 IU daily for 14 days as loading dose followed by 4000 IU daily) or standard-dose vitamin D3 (400 IU/d). The primary end point was PFS [progression free survival], while secondary end points included objective response rate, overall survival, and toxicity.

TAKEAWAY

  • Among 455 randomized patients with median follow-up of 20 months, median PFS [progression free survival] for high-dose vitamin D3 (n = 228) was 11.8 months vs 10.3 months for standard-dose vitamin D3 (n = 227).
  • No significant differences were observed in objective response rates between high-dose and standard-dose vitamin D3 groups (51% vs 44%) or in overall survival (median, 25.6 vs 27.0 months).

IN PRACTICE

“On the basis of these findings, the addition of high-dose vitamin D to standard chemotherapy cannot be recommended for unselected patients with previously untreated mCRC…. However, these findings remain exploratory and require further investigation,” the authors of the study wrote.

Leave a Reply

Your email address will not be published. Required fields are marked *